
### [MONDO:0002510](http://purl.obolibrary.org/obo/MONDO_0002510)
**Label:** germ cell and embryonal cancer

**Subclasses:** [MONDO:0018944](http://purl.obolibrary.org/obo/MONDO_0018944) (gestational trophoblastic neoplasm), [MONDO:0020549](http://purl.obolibrary.org/obo/MONDO_0020549) (invasive hydatidiform mole), [MONDO:0009273](http://purl.obolibrary.org/obo/MONDO_0009273) (hydatidiform mole, recurrent, 1), [MONDO:0016787](http://purl.obolibrary.org/obo/MONDO_0016787) (epithelioid trophoblastic tumor), [MONDO:0016740](http://purl.obolibrary.org/obo/MONDO_0016740) (choriocarcinoma of the central nervous system), [MONDO:0003509](http://purl.obolibrary.org/obo/MONDO_0003509) (pineal region choriocarcinoma), [MONDO:0013671](http://purl.obolibrary.org/obo/MONDO_0013671) (hydatidiform mole, recurrent, 2), [MONDO:0003507](http://purl.obolibrary.org/obo/MONDO_0003507) (choriocarcinoma of ovary), [MONDO:0003508](http://purl.obolibrary.org/obo/MONDO_0003508) (choriocarcinoma of the testis), [MONDO:0003506](http://purl.obolibrary.org/obo/MONDO_0003506) (pulmonary artery choriocarcinoma), [MONDO:0002599](http://purl.obolibrary.org/obo/MONDO_0002599) (teratocarcinoma), [MONDO:0003966](http://purl.obolibrary.org/obo/MONDO_0003966) (testicular monophasic choriocarcinoma), [MONDO:0004535](http://purl.obolibrary.org/obo/MONDO_0004535) (childhood choriocarcinoma of the ovary), [MONDO:0005207](http://purl.obolibrary.org/obo/MONDO_0005207) (choriocarcinoma (disease)), [MONDO:0002871](http://purl.obolibrary.org/obo/MONDO_0002871) (testicular trophoblastic tumor), [MONDO:0003786](http://purl.obolibrary.org/obo/MONDO_0003786) (childhood testicular choriocarcinoma), [MONDO:0002872](http://purl.obolibrary.org/obo/MONDO_0002872) (trophoblastic neoplasm), [MONDO:0006871](http://purl.obolibrary.org/obo/MONDO_0006871) (non-gestational choriocarcinoma), [MONDO:0006374](http://purl.obolibrary.org/obo/MONDO_0006374) (placental choriocarcinoma), [MONDO:0004294](http://purl.obolibrary.org/obo/MONDO_0004294) (gestational ovarian choriocarcinoma), [MONDO:0004490](http://purl.obolibrary.org/obo/MONDO_0004490) (gestational uterine corpus choriocarcinoma), [MONDO:0004491](http://purl.obolibrary.org/obo/MONDO_0004491) (uterine corpus choriocarcinoma), [MONDO:0020552](http://purl.obolibrary.org/obo/MONDO_0020552) (placental site trophoblastic tumor), [MONDO:0003952](http://purl.obolibrary.org/obo/MONDO_0003952) (adult central nervous system choriocarcinoma), [MONDO:0004489](http://purl.obolibrary.org/obo/MONDO_0004489) (fallopian tube gestational choriocarcinoma), [MONDO:0004322](http://purl.obolibrary.org/obo/MONDO_0004322) (non-gestational ovarian choriocarcinoma), [MONDO:0006445](http://purl.obolibrary.org/obo/MONDO_0006445) (testicular choriocarcinoma), [MONDO:0006222](http://purl.obolibrary.org/obo/MONDO_0006222) (gastric choriocarcinoma), [MONDO:0020550](http://purl.obolibrary.org/obo/MONDO_0020550) (gestational choriocarcinoma), 

**Mapped go classes:** [GO:0043280](http://purl.obolibrary.org/obo/GO_0043280) (positive regulation of cysteine-type endopeptidase activity involved in apoptotic process), [GO:0000166](http://purl.obolibrary.org/obo/GO_0000166) (nucleotide binding), [GO:0005524](http://purl.obolibrary.org/obo/GO_0005524) (ATP binding), [GO:0005737](http://purl.obolibrary.org/obo/GO_0005737) (cytoplasm), [GO:0032088](http://purl.obolibrary.org/obo/GO_0032088) (negative regulation of NF-kappaB transcription factor activity), [GO:0043231](http://purl.obolibrary.org/obo/GO_0043231) (intracellular membrane-bounded organelle), [GO:0050718](http://purl.obolibrary.org/obo/GO_0050718) (positive regulation of interleukin-1 beta secretion), [GO:0005829](http://purl.obolibrary.org/obo/GO_0005829) (cytosol), [GO:0005794](http://purl.obolibrary.org/obo/GO_0005794) (Golgi apparatus), [GO:0042981](http://purl.obolibrary.org/obo/GO_0042981) (regulation of apoptotic process), [GO:0032090](http://purl.obolibrary.org/obo/GO_0032090) (Pyrin domain binding), 

**Class expressions from DL-Learner:**

- [GO:0032090](http://purl.obolibrary.org/obo/GO_0032090) (Pyrin domain binding) 60.00%
- [GO:0032088](http://purl.obolibrary.org/obo/GO_0032088) (negative regulation of NF-kappaB transcription factor activity) 60.00%
- [GO:0005794](http://purl.obolibrary.org/obo/GO_0005794) (Golgi apparatus) 60.00%
- [GO:0005524](http://purl.obolibrary.org/obo/GO_0005524) (ATP binding) 60.00%
- [GO:0032559](http://purl.obolibrary.org/obo/GO_0032559) (adenyl ribonucleotide binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) 60.00%
- [GO:0030554](http://purl.obolibrary.org/obo/GO_0030554) (adenyl nucleotide binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) 60.00%
- [GO:0008144](http://purl.obolibrary.org/obo/GO_0008144) (drug binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) 60.00%
- [GO:0030554](http://purl.obolibrary.org/obo/GO_0030554) (adenyl nucleotide binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) and [GO:0097367](http://purl.obolibrary.org/obo/GO_0097367) (carbohydrate derivative binding) 60.00%
- [GO:0030554](http://purl.obolibrary.org/obo/GO_0030554) (adenyl nucleotide binding) and [GO:0032555](http://purl.obolibrary.org/obo/GO_0032555) (purine ribonucleotide binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) 60.00%
- [GO:0030554](http://purl.obolibrary.org/obo/GO_0030554) (adenyl nucleotide binding) and [GO:0032553](http://purl.obolibrary.org/obo/GO_0032553) (ribonucleotide binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) 60.00%
- [GO:0008144](http://purl.obolibrary.org/obo/GO_0008144) (drug binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) and [GO:0097367](http://purl.obolibrary.org/obo/GO_0097367) (carbohydrate derivative binding) 60.00%
- [GO:0008144](http://purl.obolibrary.org/obo/GO_0008144) (drug binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) and [GO:0036094](http://purl.obolibrary.org/obo/GO_0036094) (small molecule binding) 60.00%
- [GO:0008144](http://purl.obolibrary.org/obo/GO_0008144) (drug binding) and [GO:0032559](http://purl.obolibrary.org/obo/GO_0032559) (adenyl ribonucleotide binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) 60.00%
- [GO:0008144](http://purl.obolibrary.org/obo/GO_0008144) (drug binding) and [GO:0032555](http://purl.obolibrary.org/obo/GO_0032555) (purine ribonucleotide binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) 60.00%
- [GO:0008144](http://purl.obolibrary.org/obo/GO_0008144) (drug binding) and [GO:0032553](http://purl.obolibrary.org/obo/GO_0032553) (ribonucleotide binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) 60.00%


